AVITA Medical, Inc. (RCEL)

Market Cap	165.11M -27.5%
Revenue (ttm)	71.61M +11.5%
Net Income	-48.59M
EPS	-1.74
Shares Out	30.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	738,695
Open	4.85
Previous Close	4.85
Day's Range	4.84 - 5.92
52-Week Range	3.22 - 10.29
Beta	1.80
Analysts	Buy
Price Target	7.17 (+33.02%)
Earnings Date	Feb 12, 2026

About RCEL

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cary Vance
• Employees: 226
• Stock Exchange: NASDAQ
• Ticker Symbol: RCEL
• Website: https://avitamedical.com

Financial Performance

In 2025, AVITA Medical's revenue was $71.61 million, an increase of 11.45% compared to the previous year's $64.25 million. Losses were -$48.59 million, -21.44% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for RCEL stock is "Buy." The 12-month stock price target is $7.17, which is an increase of 33.02% from the latest price.

Price Target

$7.17

(33.02% upside)

Analyst Consensus: Buy